Ajanta Pharma has received final approval from the US health regulator for Entacapone tablets, used in the treatment of Parkinson’s disease.
In a BSE filing, Ajanta Pharma said it has recieved “final approval for Entacapone tablets from USFDA. It is a bioequivalent generic version of Comtan tablets.''
The company said it will launch the product shortly in the strength of 200mg tablets. This new approval is part of portfolio of products that the company has developed for the US market, it added.
Ajanta Pharma has 35 abbreviated new drug applications (ANDAs) of which it has final approval for 20 ANDAs, tentative approval for 2 ANDAs and 13 ANDAs are under review with USFDA, Ajanta Pharma said.
Shares of Ajanta Pharma were trading down by 0.45 per cent at Rs 1,195.60 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.